Stockreport

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Molecular Partners AG - American Depositary Shares  (MOLN) 
PDF Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodyna [Read more]